PBM Stock Chart & Stats
$7.60
-$0.01(-0.52%)
At close: 4:00 PM EST
$7.60
-$0.01(-0.52%)
Day’s Range― - ―
52-Week Range$1.92 - $74.94
Previous CloseN/A
Volume97.84K
Average Volume (3M)1.12M
Market Cap
$11.06M
Enterprise Value-$6.08M
Total Cash (Recent Filing)$733.00
Total Debt (Recent Filing)$10.45K
Price to Earnings (P/E)―
Beta4.96
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.94
Shares Outstanding3,814,328
10 Day Avg. Volume434,378
30 Day Avg. Volume1,123,534
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.55
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda3.94
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Psyence Biomedical News
PBM FAQ
What was Psyence Biomedical’s price range in the past 12 months?
Psyence Biomedical lowest stock price was $1.92 and its highest was $74.94 in the past 12 months.
What is Psyence Biomedical’s market cap?
Psyence Biomedical’s market cap is $11.06M.
When is Psyence Biomedical’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Psyence Biomedical’s earnings last quarter?
Currently, no data Available
Is Psyence Biomedical overvalued?
According to Wall Street analysts Psyence Biomedical’s price is currently Overvalued.
Does Psyence Biomedical pay dividends?
Psyence Biomedical does not currently pay dividends.
What is Psyence Biomedical’s EPS estimate?
Psyence Biomedical’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Psyence Biomedical have?
Psyence Biomedical has 3,814,328 shares outstanding.
What happened to Psyence Biomedical’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Psyence Biomedical?
Currently, no hedge funds are holding shares in PBM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Psyence Biomedical
Psyence Biomedical Ltd. is dedicated to advancing psychedelic medicines formulated from botanical psilocybin. The firm is actively exploring natural psilocybin as a potential therapy for adjustment disorder experienced by patients with an incurable cancer diagnosis undergoing palliative care. Its leading investigational drug, PEX010, a capsule made with naturally sourced psilocybin, is currently in a Phase IIb clinical study. This product is being developed to treat anxiety, depression, and associated conditions such as post-traumatic stress disorder (PTSD), stress, grief, and adjustment disorder, especially in a palliative care context. Psyence Biomedical has partnered with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010, utilizing psilocybin-assisted psychotherapy for adjustment disorder arising from incurable cancer. Additionally, the company holds a strategic alliance with PsyLabs for the manufacturing of Ibogaine. Headquartered in Toronto, Canada, Psyence Biomedical Ltd. functions as a subsidiary of Psyence Group Inc.
Technical Analysis
GT Biopharma
―
Revelation Biosciences
―
Dermata Therapeutics
―
CERo Therapeutics Holdings
―
Azitra Inc
―
Ownership Overview
―
Insiders
<0.01% Other Institutional Investors
96.79% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---